An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 14 Feb 2012 Biomarkers information updated
- 13 Feb 2012 Actual patient number (36) added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.